Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Wolff Pharmacology Review > Anticoagulants & Thrombolytics > Flashcards

Anticoagulants & Thrombolytics Flashcards

1
Q

purified Fab fragments of monoclonal antibody that prevent GP IIb/IIIa receptors from binding to fibrinogen

A

abciximab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

indication for GP IIb/IIIa inhibitor to limit/prevent ischemia (3 words)

A

acute coronary syndromes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

indication for alteplase, especially when within 3-6 hrs and option of percutaneous coronary intervention is unavailable (3 words)

A

acute myocardial infarction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

platelet derived ligand for autocrine/paracrine stimulation of P2Y12 receptors

A

ADP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

glycoprotein produced via recombinant DNA technology that is identical in aa sequence to human tissue plasminogen activator

A

alteplase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

a treatment for bleeding, it prevents activation of plasminogen and directly inhibits plasmin (2 words)

A

aminocaproic acid

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

no reliable way to monitor the degree of this for either dabigatran or rivaroxaban

A

anticoagulation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

recombinant human form purified from goat’s milk is available for those with deficiency, but it is expensive

A

antithrombin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

contraindication for alteplase (2 words)

A

aortic dissection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

laboratory test used to monitor the anticoagulant activity of heparin; ideally kept at 1.5-2 but can be a challenge since heparin has highly variable plasma levels due a short half-life and multiple sites of nonspecific binding, some of which can hasten its clearance

A

aPTT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

hirudin analog administered IV for the prophylaxis and treatment of thrombosis in patients with or at great risk for developing heparin-induced thrombocytopenia

A

argatroban

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

irreversibly blocks the synthesis of thromboxane A2 by platelets, one of the agents that promotes the activation and aggregation of platelets; taking this at low-doses for cardiovascular prophylaxis is now (as of March 2019) no longer recommended for anyone without clinical signs of heart disease or stroke

A

aspirin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

a synthetic peptide similar to leech anticoagulant hirudin, it is a direct inhibitor of thrombin, but class as a whole has had limited use since must be administered intravenously and much more expensive than heparin

A

bivalirudin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

risk of this can be reduced during alteplase administration by minimizing physical manipulation of the patient, avoiding subQ and IM injections, and minimizing concurrent use of anticoagulants and antiplatelet drugs

A

bleeding

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

obvious and effective treatment for bleeding (2 words)

A

blood replacement

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

type 3 phosphodiesterase inhibitor used to suppress platelet aggregation, indicated for intermittent claudication

A

cilostazol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

among the best selling drugs in the world, it suppresses platelet aggregation by irreversibly blocking P2Y12 receptors

A

clopidogrel

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

depending on risk for this, a daily dose of aspirin may be indicated (3 words)

A

coronary heart disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

blocking stenosis here is an indication for clopidogrel (2 words)

A

coronary stents

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

enzyme thought to be responsible for synthesis of platelet inhibitor PGI2 by endothelial cells; its selective sparing by low doses of aspirin is thought to explain the cardiovascular benefits of aspirin and the adverse effects associated with withdrawn drug rofecoxib

A

COX2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

needed by clopidogrel for activation and inhibited by proton pump inhibitors; reason Prilosec media mention Plavix and vice versa

A

CYP2C19

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

orally active and reversible direct inhibitor of thrombin

A

dabigatran

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

low-molecular weight heparins are now the dugs of first choice for the treatment and prevention of this (3 words)

A

deep venous thrombosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

dabigatran is unstable and must be stored in this type of bottle, also avoiding excess heat or cold

A

desiccator

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

a vasopressin V2 analog that can be useful for treating VWD and hemophilia, it promotes release of vWF and factor VII

A

desmopressin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

abbr. for condition treated with heparin

A

DIC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

suppresses platelet aggregation via uncertain mechanism (PDE inhibitor?), synergizes with aspirin and used in combination to prevent recurrent ischemic stroke in patients with TIA or past stroke

A

dipyridamole

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

warfarin has a multitude of these that can influence its activity and mandates regular testing and additional testing whenever changes are made to the daily treatment regimen (2 words)

A

drug interactions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

example of a low-molecular weight heparin made by depolymerizing heparin; with its shorter chain length, its binding to antithrombin inhibits factor Xa but is generally unable to form the ternary complex with thrombin needed for its inhibition

A

enoxaparin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

small peptide inhibitor of GP IIb/IIIa receptor approved for use during acute coronary syndromes and percutaneous coronary intervention

A

eptifibatide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

substrate for plasmin

A

fibrin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

bridging molecule between activated gp IIb/IIIa receptors on platelets

A

fibrinogen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

synthetic pentasaccharide, the minimum sequence needed to bind to antithrombin and inhibit factor Xa; sequence is too short to form the ternary complex with thrombin that is needed to inhibit thrombin activity

A

fondaparinux

34
Q

platelet receptors that allow the platelets to link together (aggregate), drugs that block these receptors block the final common pathway of platelet aggregation and are therefore the most effective antiplatelet drugs

A

GPIIb/IIIa

35
Q

sequence of letters in a generic drug name that suggests blockade of P2Y12 receptors

A

grel

36
Q

the use of heparin increases the risk for one of these forming and damaging the brain or spinal cord

A

hematoma

37
Q

a mixture of long highly negatively charged polysaccharide chains isolated from bovine lung or porcine intestine, a pentasaccharide sequence randomly distributed along its length binds to antithrombin to facilitate its inhibition of factor Xa and thrombin

A

heparin

38
Q

when severe and uncontrolled, a relative contraindication for alteplase

A

hypertension

39
Q

lower than 2 and the risk for thromboembolism increases in patients treated with warfarin while higher than 3 and risk of intracranial hemorrhage increases

A

INR

40
Q

not required for dabigatran or rivaroxaban (2 words)

A

INR monitoring

41
Q

contraindication for alteplase and most serious concern with its use (2 words)

A

intracranial hemorrhage

42
Q

contraindication for alteplase unless has occurred within past 3 hrs, when it is an indication (2 words)

A

ischemic stroke

43
Q

duration of clopidogrel and aspirin effects on platelets

A

lifetime

44
Q

dabigatran was found to be inferior to warfarin at inhibiting thromboembolism in these (3 words)

A

mechanical heart valves

45
Q

warfarin has the potential to cause this in skin, occurs when rapid fall in protein C leads to a hypercoagulable state

A

necrosis

46
Q

indication for rivaroxaban or dabigatran (3 words)

A

nonvalvular atrial fibrillation

47
Q

seeing this sequence of letters in a generic drug name suggests product is some sort of heparin analog

A

parin

48
Q

procedure (abbr.) that is indication for a GP IIb/IIIa inhibitor, which is used to prevent rapid re-occlusion

A

PCI

49
Q

because predictable for both fondaparinux and low-molecular weight heparins, these agents can be self-administered at home

A

pharmacokinetics

50
Q

generic ending of name for drugs that function as tissue plasminogen activators

A

plase

51
Q

when clot-bound, converted by alteplase to enzyme responsible for clot breakdown

A

plasminogen

52
Q

breaks down a blood clot when bound to it, when circulating it breaks down various clotting factors unless bound by alpha2-antiplasmin

A

plasmin

53
Q

a P2Y12 inhibitor similar to clopidogrel and competing for market share

A

prasugrel

54
Q

platelet Fc receptors bind an IgG bound to heparin and this in heparin-induced thrmobocytopenia, leads to platelet activation/thrombosis and platelet removal by splenic macrophages

A

platelet factor 4

55
Q

reason for selecting heparin (i.e., due to its inability to cross membrane barriers) as anticoagulant rather than warfarin

A

pregnancy

56
Q

vitamin K-dependent anti-clotting factor with shorter half-life than several other factors, its disappearance is reason warfarin adminstration can cause a pro-coagulant phase

A

protein C

57
Q

antidote for “oops, too much heparin”

A

protamine

58
Q

aspirin has this for ischemic strokes, transient ischemic attacks, stable and unstable angina and myocardial infarction among others (2 words)

A

proven efficacy

59
Q

indication for alteplase if acute and massive (2 words)

A

pulmonary embolism

60
Q

advantage of dabigatran and rivaroxaban in comparison to warfarin (2 words)

A

rapid onset

61
Q

ticagrelor differs from clopidogrel by causing this type of P2Y12 receptor block

A

reversible

62
Q

a direct inhibitor of activated factor X, it therefore rapidly inhibits the generation of thrombin from prothrombin

A

rivaroxaban

63
Q

characteristic of both onset and offset of warfarin’s anticoagulant effects

A

slow

64
Q

doing this near eye, brain or spinal cord is a contraindication for anticoagulants

A

surgery

65
Q

potent activator of platelets; it exerts these effects by cleaving a peptide from protease activated receptors (PAR1, PAR4) on the platelet surface, thereby allowing the ligand tethered to the GPCR to activate the receptor

A

thrombin

66
Q

can be induced by unfractionated heparin and low-molecular weight heparin; fondaparinux will not induce but should not be used as a replacement anticoagulant as it can exacerbate the situation

A

thrombocytopenia

67
Q

useful for diagnosing heparin-induced thrmbocytopenia, expect onset between days 5-14 after heparin exposure

A

timing

68
Q

prevention of this and its potential adverse consequences is a common reason for taking warfarin (2 words)

A

venous thrombosis

69
Q

required for synthesis of biologically active clotting factors II, VII, IX, X, protein C and protein S among others, and antidote for warfarin (2 words)

A

vitamin K

70
Q

newly approved (5/2014) reversible (but long half-life) PAR1 antagonist indicated for reduction of thrombotic cardiovascular events in patients with history of myocardial infaction or with peripheral arterial disease; life-threatening/fatal bleeding is a side effect that will limit its use

A

vorapaxar

71
Q

exerts its slow onset anticoagulation effects by blocking the conversion of vitamin K epoxide to its active reduced form; depletion of biologically active vitamin K results in an inability to post-translationally carboxylate specific glutamate residues and results in enzyme proteins with a non-functional active site

A

warfarin

72
Q

type of bleeding seen primarily at platelet counts below 10,000/microL

A

spontaneous

73
Q

comparative color of arterial clots

A

white

74
Q

type of bleeding common with platelet defects (along with rapid/greater bleeding from cuts)

A

mucocutaneous

75
Q

common with platelet defects, uncommon with clotting factor defects

A

petechiae

76
Q

bleeds here (e.g., hematomas) are a common manifestation of clotting factor deficiencies

A

deep tissue

77
Q

leading to decreased levels of VKORC1 (vitamin K epoxide reducatase complex subunit 1), this is found in ~90% of asians and is why they are more sensitive to warfarin than blacks (~14% incidence)

A

genetic variability

78
Q

metabolizes the more potent S-warfarin to 7-OH-warfarin; there are numerous polymorphisms in this gene and those decreasing its activity against warfarin are more common (10-20%) in caucasians, increasing warfarin potency 3-5X

A

CYP2C9

79
Q

a challenge for both heparin and warfarin, reason that frequent coagulation tests are required

A

dosing

80
Q

humanized antibody recently available to neutralize/serve as an antidote for dabigatran

A

idarucizumab

81
Q

recently approved as a reversal agent for factor Xa inhibitors rivaroxaban and apixaban

A

andexanet alfa

82
Q

second physiological activator of plasminogen activator to degrade clotting factors, acts in fluid phase/extravascular compartment; was withdrawn from market but now back for treatment of pulmonary embolism needing a clot buster

A

urokinase

Wolff Pharmacology Review (12 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions